SAN DIEGO, Sept. 26, 2016 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drugdevelopment company, announces that its lead antibody development program, HuMab 5B1, was featured in three separate presentations at the recently held World Molecular Imaging Congress (WMIC) in September. The presentations were made by investigators
Summaries of the investigator presentations and key points made are as follows:
David Hansen, CEO of MabVax Therapeutics, said, "We are grateful to Jason S. Lewis, Ph.D. and his team for their continued pioneering work using the HuMab-5B1 platform. They are taking important steps in expanding the clinical utility of our HuMab-5B1 antibody, including (1) demonstrating that smaller fragments of our full-length antibody could provide significant advantages in speeding tumor imaging, (2) demonstrating the utility of our full length antibody with a new radioimmunotherapy approach, (3) helping MabVax to evaluate additional CA19-9 expressing cancers for which our antibody development program may have utility beyond our current focus on pancreatic cancer, and (4) completing investigations supporting our radioimmunotherapy product for which we plan to submit an Investigational New Drug Application later this year."
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with the Company's proprietary vaccines. MabVax's HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a phase I trial at Memorial Sloan Kettering Cancer Center, or MSK. In preclinical research, the 5B1 antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers. The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer. MabVax's two lead antibody clinical programs, currently in phase I clinical trials, utilize HuMab-5B1 as a therapeutic antibody (MVT-5873) and as an immuno-PET imaging agent (MVT-2163). Additional information is available at www.mabvax.com.
Forward Looking Statements
This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's lead development program, HuMab 5B1, and clinical development candidates MVT-5873, and MVT-2163. We have no assurance that all of the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its Annual Report on Form 10-K for the fiscal year ended December 31, 2014, the Company's Quarterly Reports on Form 10-Q, the Company's Definitive Proxy Statement on Form 14A filed July 27, 2015, as such filings may be amended and supplemented from time to time, and other filings and reports by the Company with the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.
Contact: MabVax Investor Relations1-866-976-4784
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mabvax-therapeutics-humab-5b1-based-diagnostic-imaging-and-radioimmunotherapy-programs-featured-at-the-2016-world-molecular-imaging-congress-300333755.html
SOURCE MabVax Therapeutics Holdings, Inc.
Subscribe to our Free Newsletters!
HELLP syndrome is a rare but serious complication that affects pregnant women. If detected on time, ...
Discectomy is a surgical procedure in which a herniated (bulged) disc that compresses the nerves of ...
Parotidectomy is a surgery to remove a part of or the entire parotid salivary gland, on the side of ...View All